Review
Medicine, General & Internal
Haocheng Lu, Jinjian Sun, Milton H. Hamblin, Y. Eugene Chen, Yanbo Fan
Summary: TFEB, a member of the MITF family, has been shown to regulate homeostasis in the cardiovascular system and have beneficial effects on cardiovascular diseases, making it a promising molecular target for treatment.
Article
Gastroenterology & Hepatology
Bruce E. Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, Peter D. R. Higgins, Monika Fischer, Vipul Jairath, Fumihito Hirai, Geert D'Haens, Ruth M. Belin, Debra Miller, Elisa Gomez-Valderas, April N. Naegeli, Jay L. Tuttle, Paul F. Pollack, William J. Sandborn
Summary: Mirikizumab demonstrates efficacy and safety in patients with moderate-to-severe Crohn's disease. Significant endoscopic response is observed in the Mirikizumab groups compared to the placebo group at Week 12 and is sustained through Week 52. The frequency of adverse events is similar between Mirikizumab and placebo groups.
Review
Pharmacology & Pharmacy
Dhanu Gupta, Antje Maria Zickler, Samir El Andaloussi
Summary: This study analyzed 64 pre-clinical studies on EV-based therapeutics and found variations in dosing strategies regardless of EV purification method. Disease models influenced dose discrepancies, showing a need for qualitative consideration in EV dosing. Recommendations were made to focus on qualitative aspects like therapeutic cargo potency for better reliability and reproducibility in EV-based therapeutics.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Review
Pharmacology & Pharmacy
Ju-Xian Song, Jia Liu, Yimin Jiang, Zi-Ying Wang, Min Li
Summary: TFEB as a master regulator of the autophagy-lysosomal pathway holds therapeutic potential for neurodegenerative disorders, with small molecules identified as TFEB activators showing promise in protecting against these diseases. Research is ongoing and the development of specific and potent TFEB activators with ideal brain bioavailability could provide a method for treating neurodegenerative disorders.
DRUG DISCOVERY TODAY
(2021)
Review
Oncology
Claire Breal, Frederic Beuvon, Thibault de Witasse-Thezy, Solene Dermine, Patricia Franchi-Rezgui, Benedicte Deau-Fisher, Lise Willems, Eric Grignano, Adrien Contejean, Didier Bouscary, Jean Luc Faillie, Jean-Marc Treluyer, Corinne Guerin, Laurent Chouchana, Marguerite Vignon
Summary: The PI3K pathway is crucial in cancer progression and immunity. Idelalisib was the first approved drug in this class, followed by second-generation inhibitors copanlisib, duvelisib, and umbralisib in the US. However, real-world data on PI3K inhibitor-induced colitis are lacking. This review summarizes the landscape of PI3K inhibitors in hematological malignancies and their gastrointestinal side effects reported in clinical trials, as well as worldwide pharmacovigilance data. The authors also present their own real-world experience in managing idelalisib-induced colitis.
Article
Immunology
Debjeet Sur, Arpan Dutta, Chaitali Mondal, Apurba Banerjee, Pallab Kanti Haldar, Himangshu Sekhar Maji, Asis Bala
Summary: The study revealed that MAOI Selegiline can improve symptoms and progression of rheumatoid arthritis by reducing the release of inflammatory cytokines and arthritis score. Furthermore, Selegiline significantly decreased serum levels of IL-6 and TNF-alpha, suggesting its potential as a new drug for the treatment of RA in the future.
INFLAMMOPHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Ziteng Wang, Eric Chun Yong Chan
Summary: Research evaluated dosing strategies of baricitinib and tofacitinib for COVID-19 treatment in elderly patients, showing that current dosage adjustments based on renal functions are broadly adequate for elderly populations, but may need to reduce the recommended dose of baricitinib in White older subjects.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Multidisciplinary Sciences
Chanyapat Kaewsaengeak, Usanee Pienputtarapong, Teerapong Tocharoenchok
Summary: The study found that there is no significant difference in time in therapeutic range, warfarin dosage, compliance, INR, and complications between the split tablet and alternate-day dosing regimens of warfarin. Both methods are comparable in their effectiveness.
SCIENTIFIC REPORTS
(2021)
Article
Surgery
Justin C. M. Chua, Peter F. Mount, Darren Lee
Summary: Lowering the starting tacrolimus dose resulted in a higher proportion of kidney transplant recipients achieving therapeutic levels and minimized dose changes in the early posttransplant period without impacting clinical outcomes.
CLINICAL TRANSPLANTATION
(2022)
Article
Biophysics
Jun Jie Ong, Thomas D. Pollard, Alvaro Goyanes, Simon Gaisford, Mohammed Elbadawi, Abdul W. Basit
Summary: Optical biosensors are poised to revolutionize the medical industry, with successful applications in health monitoring and potential benefits in drug detection and monitoring. Personalized dosing using optical biosensors has the ability to significantly improve patient lives.
BIOSENSORS & BIOELECTRONICS
(2021)
Article
Infectious Diseases
Ute Chiriac, Daniel C. Richter, Otto R. Frey, Anka C. Roehr, Sophia Helbig, Judit Preisenberger, Stefan Hagel, Jason A. Roberts, Markus A. Weigand, Alexander Brinkmann
Summary: Optimizing antibiotic dosing through software-guided empiric dosing and therapeutic drug monitoring can enhance therapeutic exposure of piperacillin in critically ill patients with sepsis and septic shock, leading to improved clinical outcomes and reduced mortality rates.
Article
Immunology
Manjunath P. Pai, Pier Giorgio Cojutti, Valentina Gerussi, Paola Della Siega, Carlo Tascini, Federico Pea
Summary: Linezolid-induced myelosuppression is likely to occur in cardiosurgical patients due to reduced kidney function and potential drug interactions. Population modeling and simulation demonstrate that lower doses coupled with therapeutic drug monitoring are necessary in this vulnerable population. Thus, reducing the empiric linezolid doses in cardiosurgical patients may help avoid toxicities, and further studies are needed to verify potential drug interactions.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Guo-Fen Re, Jie Jia, Yu Xu, Zunyue Zhang, Zhen-Rong Xie, Deshenyue Kong, Danfeng Lu, Yue Li, Qing-Yan Peng, Juehua Yu, Yi-Qun Kuang, Kun-Hua Wang
Summary: Drug withdrawal induces immune responses, with broad and strong inflammatory responses occurring in the early stage and a downtrend in inflammatory responses with withdrawal time extension. Immune dysregulation may persist for over 12 months in heroin and METH users.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Guofang Shen, Kao Tang Ying Moua, Kathryn Perkins, Deron Johnson, Arthur Li, Peter Curtin, Wei Gao, Jeannine S. McCune
Summary: Sirolimus, a mTOR inhibitor, is prescribed to treat various diseases in children. Precision dosing through therapeutic drug monitoring is the current standard of care, but variability in pharmacokinetics, toxicity, and effectiveness still exists. Model-informed precision dosing and pharmacogenomic tools should be further explored. Point-of-care quantitation of sirolimus using dried blood spots is not recommended.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Chun- Wang, Pei-Ming Chu, Yi-Li Chen, Yang-Hsiang Lin, Cheng-Yi Chen
Summary: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide, often associated with inflammation and drug resistance post-chemotherapy. Understanding the role of cytokines in HCC pathogenesis can help overcome inflammatory reactions and cytokine secretion, ultimately counteracting chemotherapeutic resistance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)